Allergan buys Oculeve; plans to launch new tear-stimulator by 2017
This article was originally published in Clinica
Executive Summary
Eye-care giant Allergan will pay $125m plus milestones to acquire Oculeve, a Stanford University spinout working on the OD-01 nasal neurostimulation device that promotes tear-production.